WFRF:(D´arcy Padraig)
Search: WFRF:(D´arcy Padraig) > (2017) > Proteasome-associat...
- 2 of 3
- Previous record
- Next record
- To hitlist
Proteasome-associated deubiquitinases and cancer
-
- Mofers, Arjan (author)
- Linköpings universitet,Avdelningen för läkemedelsforskning,Medicinska fakulteten
-
- Pellegrini, Paola (author)
- Karolinska Institutet,Linköpings universitet,Avdelningen för läkemedelsforskning,Medicinska fakulteten
-
- Linder, Stig (author)
- Karolinska Institutet,Linköpings universitet,Avdelningen för läkemedelsforskning,Medicinska fakulteten,Karolinska Institute, Sweden
- show more...
- show less...
- (creator_code:org_t)
- 2017-11-14
- 2017
- English.
- In: Cancer Metastasis Review. - : SPRINGER. - 0167-7659 .- 1573-7233. ; 36:4, s. 635-653
- Research review (peer-reviewed)
Abstract
Subject headings
Close
- Maintenance of protein homeostasis is a crucial process for the normal functioning of the cell. The regulated degradation of proteins is primarily facilitated by the ubiquitin proteasome system (UPS), a system of selective tagging of proteins with ubiquitin followed by proteasome-mediated proteolysis. The UPS is highly dynamic consisting of both ubiquitination and deubiquitination steps that modulate protein stabilization and degradation. Deregulation of protein stability is a common feature in the development and progression of numerous cancer types. Simultaneously, the elevated protein synthesis rate of cancer cells and consequential accumulation of misfolded proteins drives UPS addiction, thus sensitizing them to UPS inhibitors. This sensitivity along with the potential of stabilizing pro-apoptotic signaling pathways makes the proteasome an attractive clinical target for the development of novel therapies. Targeting of the catalytic 20S subunit of the proteasome is already a clinically validated strategy in multiple myeloma and other cancers. Spurred on by this success, promising novel inhibitors of the UPS have entered development, targeting the 20S as well as regulatory 19S subunit and inhibitors of deubiquitinating and ubiquitin ligase enzymes. In this review, we outline the manner in which deregulation of the UPS can cause cancer to develop, current clinical application of proteasome inhibitors, and the (pre-)clinical development of novel inhibitors of the UPS.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinska och farmaceutiska grundvetenskaper -- Cell- och molekylärbiologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Basic Medicine -- Cell and Molecular Biology (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Keyword
- Ubiquitin; Proteasome; Deubiquitinases; Cancer
Publication and Content Type
- ref (subject category)
- for (subject category)
Find in a library
- Cancer Metastasis Review (Search for host publication in LIBRIS)
To the university's database
- 2 of 3
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- Mofers, Arjan
- Pellegrini, Paol ...
- Linder, Stig
- D´arcy, Padraig
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
- MEDICAL AND HEAL ...
- and Basic Medicine
- and Cell and Molecul ...
-
- MEDICAL AND HEALTH SCIENCES
- MEDICAL AND HEAL ...
- and Clinical Medicin ...
- and Cancer and Oncol ...
- Articles in the publication
- Cancer Metastasi ...
- By the university
- Linköping University
- Karolinska Institutet
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
